Lipid disorders - the comparison between general population and haemodialyzed patients. Will the Oral Fat Tolerance

Aleksandra Cader1, Joanna Stępniewska1, Jacek Różański1

  • 1Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.

Acta Biochimica Polonica
|December 15, 2022
PubMed

Insights

Cardiovascular disease is common in chronic kidney disease (CKD). This review explores lipid disorders in hemodialysis patients, noting a complex relationship with mortality and the potential of the Oral Fat Tolerance Test for improved diagnosis.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Chemistry

Background:

  • Cardiovascular events are frequent complications in chronic kidney disease (CKD).
  • Lipid disorders are established risk factors for cardiovascular disease (CVD) in the general population.
  • The relationship between lipid profiles and cardiovascular mortality in hemodialysis patients is complex and debated, with some studies suggesting 'reverse epidemiology'.

Approach:

  • This review evaluates current knowledge on lipid profile abnormalities in hemodialysis patients.
  • It examines the impact of hemodialysis and CKD-associated metabolic abnormalities on dyslipidemia.
  • The limitations of current fasting and non-fasting lipid profile assessments are discussed.

Key Points:

  • Approximately one-third of hemodialysis patients exhibit lipid profile abnormalities, most commonly hypertriglyceridemia.
  • The hemodialysis process itself can contribute to dyslipidemia.
  • The 'reverse epidemiology' phenomenon in hemodialysis patients complicates the interpretation of lipid profiles.

Conclusions:

  • Current methods for assessing lipid profiles in hemodialysis patients have limitations.
  • The Oral Fat Tolerance Test (OFTT) is proposed as a novel tool for improved diagnosis of postprandial hypertriglyceridemia.
  • Further research into OFTT's clinical utility in this population is warranted.